Get it on Google Play

ZymoGenetics (Nasdaq: ZGEN) Said Studies Results Did Not Meet Criteria to Move Forward

September 10, 2009 3:17 PM EDT
ZymoGenetics, Inc. (ZGEN) disclosed in an 8-K filing that the preliminary results of the Phase 2 clinical trials, Study 27298 (or AUGUST-I) and Study 27905 (or AUGUST-II) conducted by ZymoGenetics's licensee, Merck Serono International SA, to study rheumatoid arthritis as an indication for the investigational drug atacicept did not meet the pre-specified level of disease control activity to support moving directly into Phase 3 clinical testing. Further exploratory analyses are underway and no final decision has been made by Merck Serono regarding rheumatoid arthritis as a potential indication for atacicept. The studies confirmed the biological effect of atacicept on immunoglobulin and autoantibody production and no new safety signals were observed. Clinical studies investigating atacicept in lupus and multiple sclerosis indications are currently ongoing

You May Also Be Interested In





Related Categories

FDA